More about

Nivolumab

News
November 09, 2020
2 min read
Save

Nivolumab plus ipilimumab shows benefit in advanced prostate cancer subset

Nivolumab plus ipilimumab shows benefit in advanced prostate cancer subset

Nivolumab plus ipilimumab induced durable responses among a subset of men with metastatic castration-resistant prostate cancer, according to results of the phase 2 CheckMate 650 study published in Cancer Cell.

News
October 27, 2020
9 min read
Save

Advances in treatments for genitourinary malignancies provide silver lining to 2020

Advances in treatments for genitourinary malignancies provide silver lining to 2020

This year has seen some groundbreaking advances in genitourinary oncology, particularly in the fields of prostate, kidney and urothelial cancers.

News
October 19, 2020
1 min read
Save

FDA grants priority review to Opdivo with Cabometyx for renal cell carcinoma

The FDA granted priority review to nivolumab in combination with cabozantinib for treatment of advanced renal cell carcinoma.

News
October 13, 2020
2 min read
Save

No survival benefit with nivolumab vs. chemotherapy in platinum-resistant ovarian cancer

Nivolumab did not improve overall survival compared with gemcitabine or pegylated liposomal doxorubicin in platinum-resistant ovarian cancer; however, it was better tolerated, according to results presented at ESMO Virtual Congress 2020.

News
October 09, 2020
5 min read
Save

Late effects of Hodgkin lymphoma treatment: We can still do better

Late effects of Hodgkin lymphoma treatment: We can still do better

In more than 6 years as a chief medical editor for HemOnc Today, only a few subjects have prompted me to write more than one editorial.

News
October 08, 2020
1 min read
Save

Top in hem/onc: HPV vaccination, nivolumab

Top in hem/onc: HPV vaccination, nivolumab

A recent study showed that quadrivalent HPV vaccination substantially reduced the risk for invasive cervical cancer. It was the top story in hematology/oncology last week.

News
October 07, 2020
1 min read
Save

Neoadjuvant nivolumab regimen improves response in resectable NSCLC

Neoadjuvant nivolumab regimen improves response in resectable NSCLC

The addition of nivolumab to neoadjuvant chemotherapy significantly improved the pathologic complete response rate among patients with resectable non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

News
October 02, 2020
1 min read
Save

FDA approves Opdivo-Yervoy combination for malignant pleural mesothelioma

FDA approves Opdivo-Yervoy combination for malignant pleural mesothelioma

The FDA approved nivolumab in combination with ipilimumab for the treatment of adults with unresectable malignant pleural mesothelioma, the first drug regimen approved for this population in 16 years.

News
September 29, 2020
4 min read
Save

Nivolumab may be ‘new standard’ in esophageal, gastroesophageal junction cancers

Nivolumab may be ‘new standard’ in esophageal, gastroesophageal junction cancers

Adjuvant nivolumab significantly prolonged DFS compared with placebo among patients with resected esophageal and gastroesophageal junction cancer, according to results of the CheckMate 577 trial presented during ESMO Virtual Congress 2020.

News
September 25, 2020
2 min read
Save

Nivolumab plus chemotherapy prolongs PFS in gastric, gastroesophageal junction cancer

Nivolumab plus chemotherapy prolongs PFS in gastric, gastroesophageal junction cancer

The addition of nivolumab to first-line chemotherapy significantly improved PFS, but not OS, for patients with advanced or recurrent HER2-negative gastric and gastroesophageal junction cancer, according to phase 3 study findings.

View more